Nifedipine (Adalat)

Brand change Discontinuation Active

Bayer is discontinuing Adalat, their brand of nifedipine. This affects the 10 mg, 30 mg and 60 mg presentations.

Nifedipine is a blood pressure medicine used by about 6,500 people in New Zealand.

Adalat stock has now been exhausted at supplier level. Nifedipine long-acting tablet 20 mg remains available (Nyefax Retard brand).

Alternative brands of nifedipine

PHARMAC has sourced alternative supply of nifedipine 10 mg, 30 mg, and 60 mg.

30 mg and 60 mg presentations

  • Brand: Mylan nifedipine
  • Available: 7 January 2021 - stock has arrived.
  • Pharmacodes: 30 mg 2602911 | 60 mg 2602938

10 mg presentations

  • Brand: Tensipine nifedipine
  • Available: new stock is available
  • Pharmacode: 10 mg 2603217

The Mylan and Tensipine brands are unapproved medicines in New Zealand so they must be supplied in line with section 29 of the Medicines Act 1981.

Information for people taking nifedipine

We have made two alternative brands available. They are Mylan nifedipine and Tensipine nifedipine.

If you are taking the Adalat brand of nifedipine, talk to your doctor or specialist about your treatment options.

Your doctor will advise whether the alternative brands of nifedipine are suitable for you. 

Please note, these alternatives are not approved by Medsafe. 

Learn more about taking an unapproved medicine – Health Navigator website(external link)

Key dates for prescribers and pharmacists

  • Supply of Adalat has been exhausted at supplier level. 
  • On 1 January 2021 two alternative brands of nifedipine will be listed on the Pharmaceutical Schedule.
    • Mylan nifedipine 30 mg and 60 mg long-acting tablets
    • Tensipine nifedipine 10 mg long-acting tablets
  • Stock availability:
    • Mylan brand will be available early January 2021
    • Tensipine will be available mid-January 2021. 

Information for prescribers

On 1 January 2021 we will list two alternative brands of nifedipine on the Pharmaceutical Schedule.

  • Mylan nifedipine 30 mg and 60 mg long-acting tablets
  • Tensipine nifedipine 10 mg long-acting tablets

Nifedipine is available as:

  • twice daily long-acting tablets (10 mg and 20 mg)
  • once daily long-acting tablets (30 mg and 60 mg).

Read more about prescribing nifedipine on New Zealand Formulary(external link)

The Mylan and Tensipine brands are not registered in New Zealand. They must be supplied in line with section 29 of the Medicines Act 1981. 

We know supplying a medicine under section 29 is not ideal because only medical practitioners can prescribe it. Section 29 supply was the only option because Bayer discontinued Adalat. Using these unapproved brands ensures patients can continue to access funded nifedipine.

Read the Medsafe website for more information about your obligations under section 29.

Information about section 29 on Medsafe’s website(external link)

Information about section 29 on Health Navigator website(external link)

Information for pharmacists

On 1 January 2021 we will list two alternative brands of nifedipine on the Pharmaceutical Schedule. These are unapproved medicines supplied by Mylan and Link Healthcare. 

Pharmacodes

  • Nifedipine (Tensipine brand) 10 mg, Pharmacode 2603217
  • Nifedipine (Mylan brand) 30 mg, Pharmacode 2602911
  • Nifedipine (Mylan brand) 60 mg, Pharmacode 2602938

Who to contact

If you take nifedipine, talk to your prescriber or pharmacist. PHARMAC can't advise on anyone's personal clinical circumstances.

If you have questions about the listing or funding, email enquiry@pharmac.govt.nz